Harmony Biosciences Holdings Inc (HRMY)
ROA
Obliczenia
|
2023/Q4 (31 gru 2023) |
2023/Q3 (30 wrz 2023) |
2023/Q2 (30 cze 2023) |
2023/Q1 (31 mar 2023) |
2022/Q4 (31 gru 2022) |
2022/Q3 (30 wrz 2022) |
2022/Q2 (30 cze 2022) |
2022/Q1 (31 mar 2022) |
||
|---|---|---|---|---|---|---|---|---|---|
| Zysk netto (ttm) | w tys. USD | 128 853 | 150 755 | 200 237 | 189 468 | 181 468 | 155 673 | 58 110 | 48 696 |
| Aktywa razem | w tys. USD | 811 448 | 777 766 | 760 183 | 715 092 | 673 870 | 643 464 | 505 034 | 464 005 |
| ROA | 15,88% | 19,38% | 26,34% | 26,50% | 26,93% | 24,19% | 11,51% | 10,49% |
2023/Q4 obliczenia
ROA = Zysk netto (ttm) ÷ Aktywa razem
= $128 853K ÷ $811 448K
= 15,88%
Analiza porównawcza
2023/Q4
Nazwa spółki
Symbol
ROA
Harmony Biosciences Holdings Inc
HRMY
15,88%
Amphastar Pharmaceuticals Inc
AMPH
9,09%
Arcus Biosciences Inc
RCUS
-28,04%
Catalyst Pharmaceuticals Inc
CPRX
15,19%
Corcept Therapeutics Inc
CORT
17,08%
Dynavax Technologies Corp.
DVAX
-0,64%
Ironwood Pharmaceuticals Inc
IRWD
-212,76%
Myriad Genetics, Inc.
MYGN
-22,97%
Pacira BioSciences Inc
PCRX
2,66%
Supernus Pharmaceuticals Inc
SUPN
0,10%
Xencor Inc
XNCR
-13,23%